CLINICAL_TRIALS
trial_result
· 2024-01-17
Clinical Trial Update: Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) [Phase 3]
Summary
Phase 3 safety and efficacy study of gantenerumab in early Alzheimer’s disease was terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-01-17